Literature DB >> 15959445

[Prevalence and comorbidity of psychiatric disorders in the French general population].

J-P Lépine1, I Gasquet, V Kovess, S Arbabzadeh-Bouchez, L Nègre-Pagès, G Nachbaur, A-F Gaudin.   

Abstract

INTRODUCTION: ESEMeD is the first international epidemiological study using a random sampling method that has allowed the prevalence of psychiatric disorders in France to be measured with precision and compared directly with that observed in other European countries.
OBJECTIVES: 1) To determine the 12 month and lifetime prevalence of mood -disorders, anxiety disorders and alcohol-related disorders. 2) To estimate the comorbidity between these disorders. 3) To evaluate potential demographic risk factors for these disorders.
METHODS: This was a transversal survey carried out between 2001 and 2003 of non-institutionalised subjects aged 18 or over in the general population of Germany (n = 3,555), Belgium (n = 2,419), Spain (n = 5,473), France (n = 2,894), the Netherlands (n = 2,372) and Italy (n = 4,712). In France, the sampling source was a randomly generated list of telephone numbers. Subjects were interviewed at home by professional interviewers. The WMH-CIDI questionnaire was used.
RESULTS: The participation rate was 46% for France and 61% for all six countries combined. The 12 month and lifetime prevalence rates observed were respectively 6.0% and 21,4% for major depressive episodes, 1.6% and 7.9% for dysthymia, 2.1% and 6.0% for the generalised -anxiety disorders, 1.2% and 3.0% for panic disorders, 0.6% and 1.8% for agoraphobia, 2.2% and 3.9% for post-traumatic stress disorder, 1.7% and 4.7% for social phobia, 4.7% and 11,6% for specific phobia, 0.5% and 4.1% for alcohol abuse and 0.3% and 1.6% for alcohol dependence. Mood disorders and anxiety disorders were significantly more frequent in women, whilst alcohol-related disorders were more frequent in men. The prevalence of all three types of disorder was lower in elderly subjects and in those living in a rural environment. Mood disorders and alcohol-related disorders were more frequent in individuals living alone and mood disorders more frequent in those without paid employment. 38% of subjects with mood disorder also presented an anxiety disorder or an alcohol-related disorder. The comorbidity of mood and anxiety disorders was more frequent in women, younger subjects and those living alone. The comorbidity rate in subjects with anxiety disorders was 26% and did not differ between genders. For alcohol-related disorders, there was a striking difference in comorbidity rate between men and women: 26% in the former and 67% in the latter.
CONCLUSION: This study underlines the high prevalence of mood disorders, anxiety disorders and alcohol-related disorders in France and demonstrates a high degree of comorbidity between them. For this reason, it is important to evaluate and take into account potential comorbidity in the management of individuals with psychiatric disorders.

Entities:  

Mesh:

Year:  2005        PMID: 15959445     DOI: 10.1016/s0013-7006(05)82385-1

Source DB:  PubMed          Journal:  Encephale        ISSN: 0013-7006            Impact factor:   1.291


  22 in total

1.  Psychotropic drug use among older people in general practice: discrepancies between opinion and practice.

Authors:  Andrea Lasserre; Nadia Younès; Thierry Blanchon; Inge Cantegreil-Kallen; Christine Passerieux; Guy Thomas; Christine Chan-Chee; Thomas Hanslik
Journal:  Br J Gen Pract       Date:  2010-04       Impact factor: 5.386

2.  Cohort Alcohol Use in France and the Transition from Use to Alcohol Use Disorder and Remission.

Authors:  Mathilde M Husky; Chrianna Bharat; Jean-Pierre Lépine; Viviane Kovess-Masfety
Journal:  J Psychoactive Drugs       Date:  2019-05-10

3.  Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice.

Authors:  Sarah Oddoux; Paul Violette; Jeanne Cornet; Julie Akkoyun-Farinez; Michel Besnier; Antoine Noël; Frédéric Rouillon
Journal:  Nutrients       Date:  2022-06-10       Impact factor: 6.706

4.  Long-term outcome of presymptomatic testing in Huntington disease.

Authors:  Marcela Gargiulo; Séverine Lejeune; Marie-Laure Tanguy; Khadija Lahlou-Laforêt; Anne Faudet; David Cohen; Josué Feingold; Alexandra Durr
Journal:  Eur J Hum Genet       Date:  2008-08-20       Impact factor: 4.246

5.  Disability in patients consulting for anxiety or mood disorders in primary care: response to antidepressant treatment.

Authors:  Alain Gérard; François Liard; Anne Crochard; Sylvia Goni; Bruno Millet
Journal:  Neuropsychiatr Dis Treat       Date:  2012-12-13       Impact factor: 2.570

6.  Dealing with missing data in the Center for Epidemiologic Studies Depression self-report scale: a study based on the French E3N cohort.

Authors:  Noémie Resseguier; Hélène Verdoux; Roch Giorgi; Françoise Clavel-Chapelon; Xavier Paoletti
Journal:  BMC Med Res Methodol       Date:  2013-02-21       Impact factor: 4.615

7.  Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?

Authors:  Julio Bobes; Luis Caballero; Inma Vilardaga; Javier Rejas
Journal:  Ann Gen Psychiatry       Date:  2011-03-14       Impact factor: 3.455

8.  Associations between pathological gambling and psychiatric comorbidity among help-seeking populations in Hong Kong.

Authors:  Daniel T L Shek; Elda M L Chan; Ryan H Y Wong
Journal:  ScientificWorldJournal       Date:  2012-06-18

9.  Alcohol consumption, alcohol dependence, and related mortality in Italy in 2004: effects of treatment-based interventions on alcohol dependence.

Authors:  Kevin D Shield; Jürgen Rehm; Gerrit Gmel; Maximilien X Rehm; Allaman Allamani
Journal:  Subst Abuse Treat Prev Policy       Date:  2013-06-13

10.  Association between dietary patterns and depressive symptoms over time: a 10-year follow-up study of the GAZEL cohort.

Authors:  Agnès Le Port; Alice Gueguen; Emmanuelle Kesse-Guyot; Maria Melchior; Cédric Lemogne; Hermann Nabi; Marcel Goldberg; Marie Zins; Sébastien Czernichow
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.